Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

J Virol. 2013 Dec;87(24):13892-9. doi: 10.1128/JVI.02448-13. Epub 2013 Sep 25.

Abstract

We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Viral / immunology*
  • Antibodies, Viral / pharmacology
  • Coronaviridae / drug effects
  • Coronaviridae / genetics
  • Coronaviridae / physiology*
  • Coronaviridae Infections / drug therapy
  • Coronaviridae Infections / enzymology*
  • Coronaviridae Infections / immunology
  • Coronaviridae Infections / virology*
  • Dipeptidyl Peptidase 4 / chemistry
  • Dipeptidyl Peptidase 4 / genetics
  • Dipeptidyl Peptidase 4 / immunology*
  • Epitope Mapping
  • Humans
  • Protein Binding
  • Protein Structure, Tertiary
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / metabolism
  • Virus Internalization / drug effects

Substances

  • Antibodies, Monoclonal
  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • Dipeptidyl Peptidase 4